Pas de connexion internet — affichage de la version enregistrée de la page.

Fortress Biotech…

USUSD
← Vers le screener

Fortress Biotech Inc (US:FBIO) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 1. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
fortressbiotech.com
Relations avec les investisseurs
fortressbiotech.com/investors
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège social
BAY HARBOR ISLANDS, United States
PDG
Dr. Lindsay Allan Rosenwald M.D.
Employés
34
Fondée
2006
Actions en circulation
33.35 M
Flottant
21.44 M
Capitalisation boursière
73.37 M USD
Initiés
22.7%
Investisseurs institutionnels
31.43%
Secteur d'activité (SIC)
Pharmaceutical Preparations
LEI
529900DZUWSYUURECK24
Description

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksFBIOUSD2.04 -0.49%actions ordinaires

Cours sur 3 mois

US:FBIO · USD
jour de hausse jour de baisse date de détachement du dividende date de versementSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Dividendes

Aucun versement de dividendes n'a été trouvé (vérifié le 09.10.2026). L'entreprise ne verse probablement pas de dividendes.

Actualités de cette semaine

Aucune actualité au cours de la dernière semaine. Dernière actualité : 08.09.2026.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
ROSENWALD LINDSAY A (Chi…≈13.74%4.59 M2026-03-18
WEISS MICHAEL S (Officer…≈6.82%2.28 M2026-03-18
JIN DAVID (Chief Financi…≈4.95%1.65 M2026-06-22
Vanguard Capital Managem…3.11%1.04 M2026-06-30
Opaleye Management Inc.2.67%890 0002026-06-30
VANGUARD INDEX FUNDS-Van…2.09%697 8022026-06-30
Mackenzie Financial Corp…1.67%555 6762026-06-30
GSA Capital Partners LLP1.37%458 4722026-06-30
Shikiar Asset Management…0.92%305 4692026-06-30
Geode Capital Management…0.9%300 5212026-06-30
VANGUARD INDEX FUNDS-Van…0.84%279 8912026-06-30
Blackrock Inc.0.67%224 7822026-06-30
Two Sigma Investments, L…0.64%213 7862026-06-30
LOBELL JONAH JAY (Direct…≈0.58%192 3972025-12-31
Bridgeway Capital Manage…0.53%177 3682026-06-30
Vanguard Fiduciary Trust…0.5%166 3712026-06-30
Bridgeway Funds, Inc.-Ul…0.46%152 3682026-06-30
HARVEY JIMMIE (Director)≈0.44%146 7042025-12-31
Fidelity Concord Street…0.43%143 1832026-07-31
KLEIN DOV (Director)≈0.39%130 1052025-12-31
HOENLEIN MALCOLM (Direct…≈0.35%115 7472025-12-31
LORENZ KEVIN R. (Directo…≈0.3%101 0092025-12-31
iShares Trust-iShares Mi…0.26%86 9832026-07-31
LU LUCY (Director)≈0.18%61 2732024-12-31
Fidelity Concord Street…0.15%49 3202026-07-31
Fidelity Concord Street…0.11%35 8742026-07-31
EA Series Trust-EA Bridg…0.07%25 0002026-06-30
Fidelity Concord Street…0.06%18 5502026-07-31
VANGUARD Inst. INDEX Fd.…0.05%18 0512026-06-30